A multicenter double-blind, placebo-controlled randomized trial to evaluate the safety and efficacy of bovine colostrum in the treatment of severe alcoholic hepatitis (SAH).
- 2023-08-11
- Trials 24(1)
- S S Sidhu
- A Dusseja
- Shalimar
- S Nijhawan
- D Kapoor
- O Goyal
- H Kishore
- PubMed: 37568158
- DOI: 10.1186/s13063-023-07505-8
Study Design
- Type
- Meta-Analysis
- Sample size
- n = 174
- Population
- 174 patients with severe alcoholic hepatitis (SAH) from 5 academic centers in India
- Methods
- multicenter, parallel, double-blind, randomized (1:1) placebo-controlled trial; patients receive freeze-dried bovine colostrum or placebo for 4 weeks
- Blinding
- Double-blind
- Duration
- 4 weeks
Background
Severe alcoholic hepatitis (SAH) is associated with high mortality. Numerous studies and meta-analysis have reported that corticosteroids reduce the 28-day mortality in SAH, but not the 6-month mortality. Therefore, newer treatments for SAH need to be studied. A pilot study from our group had recently treated ten patients with SAH with bovine colostrum (BC) [20 g thrice in a day for 8 weeks] and prednisolone. This therapy improved the biological functions and 3-month mortality. However, as more and more data showed the failure of corticosteroids to improve the 3- and 6-month mortality, especially in patients with high mDF and MELD scores, we planned this trial to study the safety and efficacy of BC (without corticosteroids) in the treatment of SAH.Method
This is a multicenter, parallel, double-blind, randomized (1:1) placebo-controlled trial, which will enroll 174 patients with SAH from 5 academic centers in the India. Patients will receive freeze-dried BC or placebo by random 1:1 allocation for 4 weeks. The primary outcome measure is survival at 3 months. The secondary outcome measures are survival at 1 month, change in mDF and MELD scores, change in endotoxin and cytokines (alpha TNF, IL6, and IL8) levels, number of episodes of sepsis [pneumonia, spontaneous bacterial peritonitis (SBP), cellulitis, urinary tract infection (UTI)] from baseline to 4 weeks.Discussion
This study will evaluate the safety and efficacy of bovine colostrum in improving the survival of patients with SAH.Trial registration
ClinicalTrials.gov NCT02473341. Prospectively registered on June 16, 2015.Research Insights
The secondary outcome measures are survival at 1 month
- Effect
- Neutral
- Effect size
- Small
- Dose
- 20 g thrice in a day for 4 weeks
change in endotoxin and cytokines (alpha TNF, IL6, and IL8) levels
- Effect
- Neutral
- Effect size
- Small
- Dose
- 20 g thrice in a day for 4 weeks
change in endotoxin and cytokines (alpha TNF, IL6, and IL8) levels
- Effect
- Neutral
- Effect size
- Small
- Dose
- 20 g thrice in a day for 4 weeks
change in endotoxin and cytokines (alpha TNF, IL6, and IL8) levels
- Effect
- Neutral
- Effect size
- Small
- Dose
- 20 g thrice in a day for 4 weeks
change in mDF and MELD scores
- Effect
- Neutral
- Effect size
- Small
- Dose
- 20 g thrice in a day for 4 weeks
number of episodes of sepsis [pneumonia, spontaneous bacterial peritonitis (SBP), cellulitis, urinary tract infection (UTI)] from baseline to 4 weeks
- Effect
- Neutral
- Effect size
- Small
- Dose
- 20 g thrice in a day for 4 weeks
change in endotoxin and cytokines (alpha TNF, IL6, and IL8) levels
- Effect
- Neutral
- Effect size
- Small
- Dose
- 20 g thrice in a day for 4 weeks
change in mDF and MELD scores
- Effect
- Neutral
- Effect size
- Small
- Dose
- 20 g thrice in a day for 4 weeks